Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06653426 · ClinicalTrials.gov registry record · NA
The NaBu Effect on Menstruation in Women
A NA study of Menstrual Symptoms, sponsored by Magdy Milad, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06653426: Recruiting NA study of Menstrual Symptoms, sponsored by Magdy Milad, MD.
NCT06653426 is a NA study of Menstrual Symptoms that is actively recruiting participants, run by Magdy Milad, MD. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06653426, a NA study of Menstrual Symptoms, is actively recruiting participants, sponsored by Magdy Milad, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of once-daily Sodium butyrate (NaBu) on menstrual symptoms in women. The investigators posit that the use of NaBu will reduce menstrual symptoms after taking NaBu for 12 weeks.
Primary Outcome
The primary outcome measure is the change in average menstrual symptom scores from baseline to the average scores during the 12-week timeframe of taking daily Sodium butyrate (NaBu). Participants will rate their symptoms daily during their menstrual period on a scale of 0 to 10, where 0 indicates no symptoms and 10 indicates the worst possible symptoms (e.g., intolerable pain). The average symptom scores during the 12-week treatment period will be compared to the average baseline score to assess
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Sodium Butyrate (NaBu)
Study Locations (1)
Illinois
- Northwestern University - Northwestern Medicine, Lavin Family Pavilion - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-10 |
| Phase | NA |
What NCT06653426 shows while recruiting
NCT06653426 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Menstrual Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Sodium Butyrate (NaBu) is the first listed.
NCT06653426 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06653426 about?
NCT06653426 is a clinical study titled "The NaBu Effect on Menstruation in Women". The purpose of this study is to evaluate the effect of once-daily Sodium butyrate (NaBu) on menstrual symptoms in women. The investigators posit that the use of NaBu will reduce menstrual symptoms after taking NaBu for 12 weeks.
What is the current status of trial NCT06653426?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-10-01. Estimated completion is 2025-10.
What conditions does trial NCT06653426 study?
This clinical trial studies the following conditions: Menstrual Symptoms.
What interventions are being tested in trial NCT06653426?
The interventions under investigation include: Sodium Butyrate (NaBu) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06653426?
This trial is sponsored by Magdy Milad, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06653426 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06653426's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI